RE
REVBW
REVELATION BIOSCIENCES, INC.
$0.009100
0.00%
$36.0K
No data for this timeframe.
Vol
Market Cap$36.0K
Cap SizeNano Cap
Inst. Holders5 funds
Inst. Value$4.3K
Inst. Activity1 buys / 0 sells
SEC Reports1
Recent Activity
Jun 1, 2026
SEC
Revelation Biosciences, Inc. filed an 8-K on June 1, 2026, announcing the release of an updated corporate presentation m
8-K — Impact 2/10
Inst.
UBS Group AG — DOUBLED
1,300 shares ($16.00)
Inst.
UBS Group AG — NEAR_EXIT
272 shares ($3.00)
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| Clear Street Group Inc. | — | — |
| LINDEN ADVISORS LP | $2.6K | — |
| TORONTO DOMINION BANK | $896.00 | — |
| WOLVERINE ASSET MANAGEMENT LLC | $498.00 | DOUBLED |
| CITADEL ADVISORS LLC | $285.00 | TRIM |
5 institutional holders with $4.3K total value (772,346 shares) as of 2026-Q1. Top holders: Clear, LINDEN, TORONTO.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | Clear Street Group Inc. | 247,534 | $0.00 | 0.0% | — |
| 2 | LINDEN ADVISORS LP | 338,110 | $2.6K | 61.0% | — |
| 3 | TORONTO DOMINION BANK | 99,550 | $896.00 | 20.8% | — |
| 4 | WOLVERINE ASSET MANAGEMENT LLC | 54,752 | $498.00 | 11.6% | DOUBLED +146.6% |
| 5 | CITADEL ADVISORS LLC | 32,400 | $285.00 | 6.6% | TRIM -35.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | DOUBLED | 272 | 1,300 | +377.9% | $16.00 | 2025-Q2 |
| UBS Group AG | NEAR_EXIT | 2,512 | 272 | -89.2% | $3.00 | 2025-Q1 |
| WOLVERINE ASSET MANAGEMENT LLC | DOUBLED | 22,202 | 54,752 | +146.6% | $383.00 | 2024-Q4 |
| Walleye Capital LLC | NEAR_EXIT | 187,001 | 10,074 | -94.6% | $71.00 | 2024-Q4 |
| CITADEL ADVISORS LLC | TRIM | 45,853 | 29,400 | -35.9% | $423.00 | 2024-Q3 |
| WOLVERINE ASSET MANAGEMENT LLC | TRIM | 72,202 | 22,202 | -69.3% | $333.00 | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 2.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 0.0% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 0.0% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 0.0% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 0.0% | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.